Biologics now command over 70% of the Orphan Drugs Market, driven by gene therapies, enzyme replacements, and monoclonal antibodies. Approved gene therapies for rare diseases grew from 7 in 2020 to 23 by late 2024, with 40+ candidates in pivotal trials. These therapies address previously untreatable conditions like spinal muscular atrophy and sickle cell disease. Parenteral administration...